drugset / Trial / NCT00564200
MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to analyze the efficacy of allogeneic bone marrow transplantation in a reduced-intensity manner combined with bortezomib in the treatment of multiple myeloma with bad prognosis, in order to evaluate the response and relapse rates
Timeline
- Start
- 2007-11
- Primary completion
- 2014-07
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | — |
| Background | Dexamethasone | Small molecule | — | — |
| Background | Fludarabine | Small molecule | — | — |
| Background | Melphalan | Small molecule | — | — |